Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay

Radiotherapy and Oncology

Volumn 45, Issue 2, 1997, Pages 175-182

  McLaren, Duncan B ^a,c   Pickles, Tom ^a   Thomson, Tom ^a   Olive, Peggy L ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Comet assay; Hypoxia; Nicotinamide

Indexed keywords

NICOTINAMIDE;

ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; HUMAN; HYPOXIA; METASTASIS INHIBITION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TUMOR BLOOD FLOW;

ADMINISTRATION, ORAL; BIOPSY, NEEDLE; CELL HYPOXIA; DNA DAMAGE; DNA, NEOPLASM; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; NEOPLASMS; NIACINAMIDE; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT;

EID: 0031282214     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)00110-2     Document Type: Article

References (32)

1. [1] Calcutt, G., Ting, S.M. and Preece, A.W. Tissue NAD levels and the response to irradiation or cytotoxic drugs. Br. J. Cancer 24: 380-388, 1970.
2. [2] Chaplin, D.J., Horsman, M.R. and Trotter, M.J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J. Natl. Cancer Inst. 82: 672-676, 1990.
3. [3] Hill, S.A. and Chaplin, D.J. The effect of nicotinamide on microregional blood flow within tumors assessed using laser Doppler probes. Acta Oncol. 34: 401-404, 1995.
4. [4] Honess, D., Laurence, V., Ward, R., Shaw, J. and Bleehen, N. The effects of nicotinamide and carbogen, individually or in combination, on RIF-1 tumour oxygenation. In: Tumour Oxygenation, pp. 137-144. Editors: P. Vaupel, D.K. Kelleher and M. Gunderoth. Gustav Fischer, Stuttgart, 1995.
5. [5] Hoskin, P.J., Stratford, M.R., Saunders, M.I., Hall, D.W., Dennis, M.F. and Rojas, A. Administration of nicotinamide during CHART: pnarmacokinetics, dose escalation and clinical toxicity. Int. J. Radiat. Oncol. Biol. Phys. 32: 1111-1119, 1995.
6. [6] Horsman, M.R. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol. 34: 571-587, 1995.
7. [7] Horsman, M.R., Brown, D.M., Lemmon, M.J., Brown, J.M. and Lee, W.W. Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. Int. J. Radiat. Oncol. Biol. Phys. 12: 1307-1310, 1986.
8. [8] Horsman, M.J., Chaplin, D.J. and Brown, J.M. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat. Res. 118: 139-150, 1989.
9. [9] Johnsson, G.G., Kjellen, E. and Pero, R.W. Nicotinamide as a radiosensitizer of a C3H mouse mammary adenocarcinoma. Radiother. Oncol. 1: 349-353, 1984.
10. [10] Kaanders, J.P., Pop, L.A., Marres, H.A., van der Maazen, R.W., van der Kogel, A.J. and van Daal, W.A. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. Radiother. Oncol. 37: 190-198, 1995.
11. [11] Kelleher, D.K. and Vaupel, P.W. Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in rat tumors. Int. J. Radiat. Oncol. Biol. Phys. 26: 95-102, 1993.
12. [12] Laurence, V.M., Ward, R., Dennis, I.F. and Bleehen, N.M. Carbogen breathing with nicotinamide improves the oxygen status of tumors in patients. Br. J. Cancer 72: 198-205, 1995.
13. [13] Lee, I., Boucher, Y. and Jain, R.K. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res. 52: 3237-3240, 1992.
14. [14] Lee, I. and Song, C.W. The oxygenation of murine tumor isografts and human tumor xenografts by nicotinamide. Radiat. Res. 130: 65-71, 1992.
15. 2 and radiosensitivity in three tumour lines. Int. J. Radiat. Biol. 65: 379-386, 1994.
16. [16] Olive, P.L., Banáth, J.P. and Durand, R.E. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the 'comet' assay. Radiat. Res. 122: 69-72, 1990.
17. [17] Olive, P.L. and Durand, R.E. Detection of hypoxic cells in a murine tumor with the use of the comet assay. J. Natl. Cancer Inst. 85: 707-711, 1992.
18. [18] Olive, P.L., Durand, R.E., Le Riche, J., Olivotto, I. and Jackson, S.M. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res. 53: 733-736, 1993.
19. [19] Olive, P.L., Horsman, M., Grau, C. and Overgaard, J. Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assay. Br. J. Cancer, 1997, in press.
20. [20] Olive, P.L., Trotter, T., Banáth, J.P., Jackson, S.M. and Le Riche, J. Heterogeneity in human tumour hypoxic fraction measured using the comet assay. Br. J. Cancer 74: S191-S195, 1996.
21. [21] Olive, P.L., Vikse, C.M. and Durand, R.E. Hypoxic fractions measured in murine tumors and normal tissues using the comet assay. Int. J. Radiat. Oncol. Biol. Phys. 29: 487-491, 1994.
22. [22] Pickles, T., Graham, P., Syndikus, I., Rheaume, D.E., Duncan, G.G., Green, A. et al. Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother. Oncol. 40: 245-247, 1996.
23. [23] Pigott, K., Dische, S. and Saunders, M.I. Short communication: the addition of carbogen and nicotinamide to a palliative fractionation schedule for locally advanced breast cancer. Br. J. Radiol. 68: 215-218, 1995.
24. [24] Rankin, P.W., Jacobson, E.L., Benjamin, R.C., Moss, J. and Jacobson, M.K. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J. Biol. Chem. 264: 4312-4317, 1982.
25. [25] Rojas, A., Denekamp, J., Johns, H., Kjellen, E., Tsang, R., Nilsson, P. et al. Nicotinamide as a repair inhibitor in vivo: studies using single and fractionated X-ray doses in mouse skin and kidneys. Radiat. Res. 145: 419-431, 1996.
26. [26] Stratford, M.R., Dennis, M.F., Hoskin, P.J., Saunders, M.I., Hodgkiss, R.J. and Rojas, A. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol. 35: 213-219, 1996.
27. [27] van der Maazen, R.W., Thijssen, H.O., Kaanders, J.H., de Koster, A., Keyser, A., Prick, M.J., Grotenhuis, J.A., Wesseling, P. and van der Kogel, A.J. Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother. Oncol. 35: 118-122, 1995.
28. [28] Zackrisson, B., Franzen, L., Henriksson, R., Littbrand, B., Stratford, M., Dennis, M., Rojas, A.M. and Denekamp, J. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol. 33: 377-381, 1994.
29. [29] Zhang, H. and Wheeler, K.T. Radiation-induced DNA damage in tumors and normal tissues. II. Influence of dose, residual DNA damage, and physiological factors in oxygenated cells. Radiat. Res. 140: 321-326, 1994.
30. [30] Zhang, H., Koch, C.J., Wallen, C.A. and Wheeler, K.T. Radiation-induced DNA damage in tumors and normal tissues. III. Oxygen dependence of the formation of strand breaks and DNA-protein crosslinks. Radiat. Res. 142: 163-168, 1995.
31. [31] Zheng, H. and Olive, P.L. Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues. Cancer Res. 56: 2801-2808, 1996.
32. [32] Zwelling, L.A., Kerrigan, D. and Pommier, Y. Inhibitors of poly-(adenosine diphosphoribose) synthesis slow the resealing rate of x-ray induced DNA breaks. Biochem. Biophys. Res. Commun. 104: 897-902, 1982.